Attempt to control head and neck cancer through medium-molecular weight drug discovery
Journal of Oral Biosciences · 2026-04 · 68 (2) · 100769
DOI: 10.1016/j.job.2026.100769 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Oral Biosciences, 2026-04. Verfasst von Naoki Katase. Beteiligte Einrichtung: Department of Oral Pathology, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki, Japan. Electronic address: katas…. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Intercellular Signaling Peptides and Proteins, Drug Discovery, Antineoplastic Agents. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
BACKGROUND Head and neck squamous cell carcinoma (HNSCC) arises from the squamous epithelium of the head and neck region, comprising heterogeneous lesions with distinct risk factors and diverse genetic and epigenetic alteration patterns. HNSCC is often difficult to control when lymph node metastasis has occurred, and treatment outcomes remain unsatisfactory. Elucidating the genetic and epigenetic profiles of cancer-associated genes is essential for improving clinical outcomes, yet to date the key molecules driving HNSCC progression remain unclear. HIGHLIGHT We identified dickkopf Wnt signaling pathway inhibitor 3 (DKK3) as a candidate HNSCC-specific molecule that predicts prognosis. Our findings demonstrate that DKK3 expression is significantly elevated in cancer tissues relative to normal tissues and is associated with poor prognosis. Functional analyses have revealed that DKK3 exerts oncogenic effects by activating Akt signaling, driving increased cellular proliferation, migration, and invasion. We validated DKK3 as a potential therapeutic target, and developed complementary peptides to suppress its oncogenic activity. These DKK3 complementary peptides significantly inhibit HNSCC cell proliferation, invasion, and migration at low doses without detectable side effects and, in certain aspects, displayed superior performance over conventional HNSCC treatments including cisplatin and cetuximab. CONCLUSIONS Peptide-based drug discovery, also referred to as medium-molecular-weight drug discovery, has attracted increasing attention, although few agents have reached clinical application. Our DKK3 complementary peptides are promising novel candidate therapeutics for HNSCC, raising expectations for future translational and clinical developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathology, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki, Japan. Electronic address: katase@nagasaki-u.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Katase, N. (2026). Attempt to control head and neck cancer through medium-molecular weight drug discovery. Journal of Oral Biosciences, 68(2), 100769. https://doi.org/10.1016/j.job.2026.100769
Vancouver
Katase N. Attempt to control head and neck cancer through medium-molecular weight drug discovery. Journal of Oral Biosciences. 2026;68(2):100769. doi:10.1016/j.job.2026.100769
BibTeX
@article{Katase2026,
author = {Katase, Naoki},
title = {Attempt to control head and neck cancer through medium-molecular weight drug discovery},
journal = {Journal of Oral Biosciences},
year = {2026},
volume = {68},
number = {2},
pages = {100769},
doi = {10.1016/j.job.2026.100769}
}
EUVIMED